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Bcl-2 Targets the Protein Kinase Raf-1
to Mitochondria
Hong-Gang Wang,* Ulf R. Rapp,† and John C. Reed* extracts of Xenopus laevis oocytes undergoing follicular
atresia abolishes their ability to induce apoptosis-like*The Burnham Institute
destruction of exogenous nuclei (Newmeyeret al., 1994).Program on Apoptosis and Cell Death Research
Similarly, mitochondria isolated from cells induced toLa Jolla, California 92037
undergo apoptosis can stimulate apoptosis-like de-†Institute of Medical Radiation and Cell Research
struction of naive nuclei, whereas mitochondria purifiedBayerische Julius-Maximilians-Universita¨t
from Bcl-2 overexpressing cells do not (Zamzami et al.,D097078 Wurzburg
1996). Interestingly, chemical inducers of mitochondrialFederal Republic of Germany
megapore opening (permeability transition) can induce
normal mitochondria derived from healthy cells to liber-
ate factors that result in apoptosis-like destruction ofSummary
nuclei (Zamzami et al., 1996). Moreover, release of cyto-
chrome C from mitochondria occurs during apoptosisA green fluorescent protein (GFP)–Raf-1 fusion protein
and can promote activation of proteases of the interleu-was used to show that Bcl-2 can target this kinase to
kin-1b-converting enzyme (ICE) family (Liu et al., 1996).mitochondria. Active Raf-1 fused with targeting se-
Overexpression of Bcl-2 has also been reported to pre-quences from an outer mitochondrial membrane pro-
vent the dumping of mitochondrial Ca21 into the cytosoltein protected cells from apoptosis and resulted in
of cells treated with uncouplers of oxidative phosphory-phosphorylation of BAD, a proapoptotic Bcl-2 homo-
lation (Baffy et al., 1993), a known stimulus for inducinglog. Plasma membrane–targeted Raf-1 did not protect
permeability transition in mitochondria (Bernardi et al.,from apoptosis and resulted in phosphorylation of
1994). Finally, mutant versions of Bcl-2 lacking theirERK-1 and ERK-2. Untargeted active Raf-1 improved
C-terminal TM domain inefficiently associate with mito-Bcl-2-mediated resistance to apoptosis, whereas a
chondria and are impaired in their ability to prevent cellkinase-inactive Raf-1 mutant abrogated apoptosis
death (Tanaka et al., 1993; Nguyen et al., 1994), whereassuppression by Bcl-2. Bcl-2 can therefore target Raf-1
substitution of a TM domain from the yeast outer-mito-to mitochondrial membranes, allowing this kinase to
chondrial membrane protein Mas70p restores targetingphosphorylate BAD or possibly other protein sub-
to mitochondria and returns full antiapoptotic functionstrates involved in apoptosis regulation.
(Nguyen et al., 1994).
Bcl-2 family proteins contain up to four conserved
Introduction domains: BH1, BH2, BH3, and BH4. All antiapoptotic
members of the Bcl-2 protein family contain the BH4
The Bcl-2 family of proteins consists of both inhibitors domain (Zha et al., 1996), which is typically located
and promoters of programmed cell death and apoptosis. near the N-terminus of these proteins and corresponds
Many of these proteins can interact with each other to the first amphipathic a helix in the crystal structure
through a complex network of homo- and heterodimers of the Bcl-XL protein, an antiapoptotic homolog of Bcl-2
(Sato et al., 1994; Sedlak et al., 1995). The relative ratios (Muchmore et al., 1996). In contrast, the proapoptotic
of pro- and antiapoptotic Bcl-2 family proteins deter- members of the Bcl-2 family lack BH4, with the excep-
mine the ultimate sensitivity or resistance of cells to a tion of Bcl-XS. Deletion mutants of Bcl-2 lacking the
wide variety of apoptotic signals (Oltvai and Korsmeyer, BH4 domain exhibit either loss of function or dominant-
1994). The precise biochemical mechanisms by which inhibitory activity, paradoxically promoting apoptosis
Bcl-2 family proteins exert their influence on cell life and (Borner et al., 1994; Hanada et al., 1995; Hunter et al.,
death, however, remain far from clear, though several 1996), thus indicating the functional significance of the
theories have been advanced, including regulation of BH4 domain. BH4 is not, however, required for binding
organellar Ca21 homeostasis, reactive oxygen species to either Bax or wild-type Bcl-2 protein (Hanada et al.,
production, protein transport, cysteine protease activa- 1995), suggesting that it plays a role in some other as-
tion, and mitochondrial permeability transition (Baffy et pect of Bcl-2 function.
al., 1993; Kane et al., 1993; Hockenbery et al., 1993; In addition to dimerizing with other homologous pro-
Krajewski et al., 1993; Ryan et al., 1994; Boulakia et al., teins, the Bcl-2 protein has been reported to associate
1996; Zamzami et al., 1996). with several other nonhomologous proteins, including
Bcl-2 and most of its homologs contain hydrophobic the protein kinase Raf-1 (Wang et al., 1994; Bla-
stretches of amino acids near their C-termini (transmem- gosklonny et al., 1996). Raf-1 is best known for the role
brane [TM] domains) that allow for their insertion into it plays in growth factor receptor–mediated signal trans-
intracellular membranes. Though varying among differ- duction pathways involving p21ras family proteins lo-
entcell types and particularmembers of theBcl-2 family, cated at the plasmamembrane (Daumet al., 1994).When
in general, a large proportion of these protein molecules Ras assumes an active conformation through binding
are associated with the outer mitochondrial membrane of GTP, a subpopulation of the Raf-1 protein molecules
(Krajewski et al., 1993; Gonza´lez-Garcia et al., 1994; in cells translocates from the cytosol to the plasma
Yang et al., 1995). Several observations suggest an im- membrane, via interaction with p21ras (Hall, 1994). The
portant role for mitochondria in the control of apoptosis. region on Raf-1 that binds to Ras corresponds to a
negative regulatory domain located in approximately theFor example, removal of mitochondria from cytosolic
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first third of the N-terminal length of the kinase (residues
51–149), upstream of the catalytic domain (residues
330–627) (Zhang et al., 1993). This retargeting of Raf-1
to the plasma membrane both serves as a mechanism
for locally activating this kinase and also probably helps
to bring Raf-1 into contact with relevant physiological
substrates (Stokoe et al., 1994; Leevers et al., 1994). We
provide evidence here that the Bcl-2 protein can target
Raf-1 to mitochondria, through an interaction that de-
pends on the BH4 domain in Bcl-2 and the catalytic
domain in Raf-1, thus promoting resistance to apoptosis
and altering the substrate preferences of Raf-1 in cells.
Results
Raf-1 Interaction with Bcl-2 Depends
on BH4 Domain
We examined whether removal of the BH4 domain (resi-
dues 11–33) from Bcl-2 abolished its ability to interact
with Raf-1 by using three approaches: first, binding of
in vitro translated 35S-labeled Bcl-2 or Bcl-2(DBH4)
proteins to GST–Raf-1 fusion protein; second, yeast
two-hybrid assays; and third, coimmunoprecipitation
experiments where Bcl-2 and Bcl-2(DBH4) proteins were
coexpressed with Raf-1 in Sf9 insect cells infected with
recombinant baculoviruses (Figures 1A–1C, respec-
tively). All three of these approaches demonstrated a
BH4 dependence for the interaction of Bcl-2 with Raf-1
and confirmed previous studies showing that the cata-
lytic domain of Raf-1 is necessary and sufficient for this
interaction (Wang et al., 1994). The proapoptotic protein
Bcl-XS, which contains BH4 but lacks the BH1 and BH2
domains found in most other Bcl-2 family proteins, also
can associate with Raf-1, whereas Bax (which lacks
BH4) does not.
Bcl-2 Targets Raf-1 to Mitochondria
in a BH4-Dependent Manner
in Mammalian Cells
Figure 1. Raf-1 Interaction with Bcl-2 Is Dependent on the BH4 To explore further the interaction of Bcl-2 and Raf-1,
Domain. experiments were performed in 293 epithelial cells. If
(A) Baculovirus-produced GST–Raf-1 (left) or GST–Raf-1(DCR3) Bcl-2 and Raf-1 associate in intact cells, we reasoned
(center) proteins (z5 mg) were immobilized on glutathione–
that Bcl-2 should target a portion of the Raf-1 moleculesSepharose (z20 ml) and then incubated with in vitro translated (IVT)
from the cytosol to the same membranous locations[35S]methionine-labeled Bcl-2, Bcl-2(DBH4), Bcl-Xs, or Bax proteins.
where Bcl-2 resides. To test this hypothesis, Raf-1 wasThe bound proteins were analyzed by SDS–PAGE. An equivalent
amount of in vitro translated proteins was run directly in the gel expressed as a GFP fusion protein in 293 cells, with or
(right). without Bcl-2. To simplify interpretation of the data, only
(B) Interactions of pairs of fusion proteins containing either an the catalytic domain (Cat) of Raf-1 was included, thus
N-terminal LexA DNA-binding domain (LexA) or B42 trans-activation
removing the Ras-binding domain of Raf-1 and avoidingdomain (TA) were tested by yeast two-hybrid assay using b-galac-
targeting to membranes as a result of interactions withtosidase filter assays. Three independent transformants were plated
Ras family proteins.on either galactose (Gal)- or glucose (Glu)-containing medium, to
either induce or repress, respectively, the Gal-1 promoters in the Analysisof 293 cells by fluorescence confocal micros-
two-hybrid plasmids. copy after transfection with an expression plasmid en-
(C) Coimmunoprecipitation experiments were performed by using coding the GFP–Raf-1(Cat) protein revealed a mostly
lysates prepared from Sf9 cells that had been coinfected with Raf-1
diffuse pattern of fluorescence (Figure 2a). 293 cellsand either Bcl-2, Bcl-2(DBH4), Bcl-Xs, or Bax-producing recombi-
cotransfected with expression plasmids encoding thenant baculoviruses. Immunoprecipitations were performed using ei-
GFP–Raf-1(Cat) protein and Bcl-2(DBH4) displayed thether normal rabbit serum (NRS) or polyclonal rabbit antisera specific
for Raf-1, Bcl-2, Bcl-X, or Bax. Western blots were developed with same pattern of fluorescence (Figure 2b). In contrast,
anti-Raf-1 monoclonalantibody (URP30) according to a colorimetric the fluorescence in 293 cells coexpressing GFP–Raf-
method. 1(Cat) and wild-type Bcl-2 was concentrated in punctate
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Figure 2. Bcl-2 Protein Targets Raf-1 to Mitochondria
293 cells stably expressing GFP–Raf-1(D26–303) were transiently transfected with parental pCI-Neo (a), pCI-Neo-Bcl-2(DBH4) (b), or pCI-Neo-
Bcl-2 (c–f) plasmid DNA. After z48 hr, the cells were incubated with MitoTracker dye and analyzed by fluorescence confocal microscopy
using appropriate filters for visualization of green (a–d), red (e), or combined (f) fluorescence resulting from the GFP and MitoTracker molecules.
foci in the cytosol, suggestive of association with mito- TM domain should target Raf-1 to the outer mitochon-
drial membrane without the assistance of Bcl-2. In addi-chondria or other organelles (Figure 2c). Two-color anal-
ysis using a rhodamine-like dye that is specifically im- tion, Mas70p TM–Raf-1 fusion constructs were prepared
in which lysine 375 in Raf-1, which is critical for ATPported into mitochondria (MitoTracker) confirmed that
a large portion of the GFP–Raf-1 protein molecules were binding, was mutated, thereby producing a protein with-
out kinase activity. Such kinase-inactive mutants ofassociated with mitochondria (Figures 2d–2f). In con-
trast, when the GFP protein was expressed in 293 cells Raf-1 can often function as dominant inhibitors of the
endogenous wild-type kinase (Kolch et al., 1991). Towithout appended Raf-1 sequences, only a diffuse,
mostly cytosolic staining was found; it failed to colocal- avoid complications due to the association of Raf-1 with
Ras-family proteins, both the kinase active and inactiveize with mitochondria, regardless of whether the cells
coexpressed Bcl-2 or not (data not shown). Thus, Bcl-2 Mas70p–Raf-1 fusion proteins were expressed without
the N-terminal portions of Raf-1 (residues 26–303) whichdid not cause nonspecific adsorption of GFP to mito-
chondria. Moreover, immunoblot analysis of the tran- mediate binding to Ras (hereinafter referred to as
M-Raf-1 and M-Raf-1(K375W)). As an additional control,siently transfected 293 cells confirmed production of
comparable amounts of the wild-type and DBH4 mutant the same Raf-1(D26–303) protein lacking the Ras-bind-
ing domain was fused with the CAAX box–containingBcl-2 proteins (data not shown), indicating that the fail-
ure of GFP–Raf-1(Cat) to associate with mitochondria C-terminus of K-Ras, which targets Raf-1 specifically to
the plasma membrane (Stokoe et al., 1994; Leevers etwhen coexpressed with Bcl-2(DBH4) could not be ex-
plained by inadequate production of this mutant protein. al., 1994).
These Raf-1 fusion proteins were stably expressed in
32D.3, a hemopoietic cell that is dependent on interleu-Targeting Raf-1 to Mitochondria Enhances
Its Antiapoptotic Activity kin-3 (IL-3) for its growth and survival. Immunoblot anal-
ysis of lysates prepared from these cells confirmed theThe data presented above revealed that Bcl-2 can target
Raf-1 to mitochondria but left unanswered the question production of the expected z45 kDa M-Raf-1, M-Raf-
1(K375W), and Raf-1–CAAX proteins (Figure 3A, lanesof the significance of this event for regulation of apop-
tosis. To address this issue, expression plasmids were 3–5). Targeting of the M-Raf-1 (Figure 3B) and M-Raf-
1(K375W) (data not shown) proteins tomitochondria wasconstructed that produce Raf-1 fused with the TM do-
main of the yeast outer mitochondrial membrane protein verified bysubcellular fractionation methods (Figure3B),
in which cytosolic (C), light membrane (LM), and heavyMas70p (Hase et al., 1984), with the idea that theMas70p
Cell
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Figure 3. Characterization of 32D.3 Cell Transfectants
(A) Stably transfected 32D.3 cells were analyzed by immunoblotting
(20 mg of protein) using anti-peptide antisera specific for human
Bcl-2 (bottom) or Raf-1 (top).
(B) Stably transfected 32D.3–M-Raf-1 cells were used to produce
HM, cytosolic (C), and LM fractions, which were subjected to SDS–
PAGE/immunoblotting assay (20 mg of protein per lane) using anti-
bodies specific for Raf-1 (left) or the mitochondrial protein F1- Figure 4. Effects of Mitochondrial Targeting of Raf-1 on Survival of
b-ATPase (right). 32D.3 Cells
32D.3 cells (A) or 32D.3–Bcl-2 cells (B) were stably transfected with
pcDNA-3 (Neo) or pcDNA-3 encoding active Raf-1 (D2–334), kinase-
membrane (HM) fractions were prepared and analyzed inactive Raf-1 (D26–303)(K375W), Raf-1(D26–303)-CAAX, M-Raf-1,
for the presence of Raf-1 proteins by immunoblotting. or M-Raf-1(K375W) as indicated. Cells were cultured without IL-3
The z45 kDa M-Raf-1 protein was contained entirely for various times before MTT assays (data expressed as percent
relative to time 0; mean 6 SD; n = 3). Similar results were obtainedwithin the HM fraction, where mitochondria reside (Fig-
by trypan blue dye exclusion assay (data not shown).ure 3B). In contrast, the endogenous p72-Raf-1 wild-
type protein was located mostly in the cytosolic fraction.
The kinetics of cell death were explored in cultures
studies where confirmed by flow cytometric DNA con-of these 32D.3 cells expressing the M-Raf-1 and M-Raf-
tent analysis propidium iodide–stained cells (data not1(K375W) proteins when deprived of IL-3. When com-
shown), where the proportion of cells with subdipolidpared with 32D.3-Neo cells that received only the paren-
amounts of DNA, indicative of apoptosis, was deter-tal plasmid as a control, 32D.3 cells expressing the
mined. This DNA content analysis also showed that de-M-Raf-1 protein exhibited a delay in cell death compara-
spite their prolonged survival in IL-3-deficient medium,ble to that seen in transfected 32D.3 cells overexpress-
neither 32D.3–Bcl-2 nor 32D.3–M-Raf-1 cells continueding Bcl-2 (Figure 4A). In contrast, 32D.3 cells expressing
to cycle in the absence of IL-3, and the preponderancethe M-Raf-1(K375W) protein experienced accelerated
of these cells arrested in G0/G1-phase when deprivedcell death, compared with the 32D.3–Neo control cells,
of lymphokines. Taken together, therefore, these datawhen deprived of IL-3 (Figure 4A). 32D.3 cells expressing
are consistent with the hypothesis that targeting activethe Raf-1–CAAX protein, as well as the same cells ex-
Raf-1 kinase to mitochondrial membranes can specifi-pressing Raf-1(Cat) protein lacking either a CAAX box
cally enhance cellular resistance to apoptosis, whereasor the TM domain of Mas70p (Wang et al., 1994; data
interfering with action of endogenous Raf-1 at mitochon-not shown), displayed cell death kinetics comparable
dria has the opposite effect.to those of the control transfectants (Figure 4A). The
viability of all transfectants when cultured with IL-3 was
$95% during the first 3 days of the experiment, but The M-Raf-1 and M-Raf-1(K375W) Proteins Modulate
the Antiapoptotic Activity of Bcl-2then began to decline in cultures of 32D–Neo, 32D–Raf-
1–CAAX, and 32D–M-Raf–1(K375W) cells (data not If the interaction of Bcl-2 with Raf-1 plays a role in the
regulation of apoptosis by Bcl-2, then coexpressing anshown). In addition to MTT assays, the results of these
Bcl-2-Mediated Targeting of Raf-1 to Mitochondria
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active Raf-1 kinase with Bcl-2 should enhance resis- for exploring the molecular control of apoptosis (Weil
et al., 1996). To determine whether the ability of Raf-1tance to apoptosis compared with the resistance in cells
transfected with Bcl-2 alone. Conversely, the inactive and Bcl-2 to cooperate in the suppression of apoptosis
extends beyond the paradigm of IL-3 withdrawal, theRaf-1 mutant should potentially reduce the resistance
of Bcl-2-expressing cells to apoptosis, by interfering various 32D.3 transfectants described above were cul-
tured with 1 mM staurosporine in the presence of IL-3.with the interaction of Bcl-2 with the endogenous, wild-
type Raf-1 protein. To test this hypothesis, a clone of Relative numbers of viable cells were then determined
1 day later by MTT assay.As shown inFigure 5A, approx-32D.3 that had been previously transfected with Bcl-2
by using a hygromycin-resistance marker was stably imately 1.5-fold more 32D.3–Bcl-2 cells survived treat-
ment with staurosporine than did 32D.3–Neo cells (p ,transfected with pcDNA-3 expression plasmids, produc-
ing first an active form of the Raf-1 protein consisting 0.01 by unpaired t test). The 32D.3 cells expressing the
mitochondria-targeted and constitutively active Raf-1essentially only of the catalytic domain (Cat) of Raf-
1(D2–334); second, an inactive K375W mutant Raf-1 protein M-Raf-1 withstood treatment with staurosporine
about as well as the 32D.3–Bcl-2 cells (p , 0.01 forlacking the Ras-binding domain (D26–303); or third, the
pcDNA-3 parental vector as a control (contains the M-Raf-1 versus Neo). In contrast, 32D.3 cells transfected
with a plasmid encoding the plasma membrane–tar-G418-resistance gene). It was important to eliminate
the Ras-binding domain in the K375W mutant Raf-1 pro- geted Raf-1–CAAX protein (Figure 5A) or untargeted
Raf-1(Cat) (data not shown) survived no better than thetein so as to avoid interference with Ras-regulated path-
ways that are required for cell proliferation (Kolch et al., 32D–Neo control cells. In contrast, 32D.3 cells coex-
pressing the same Raf-1(Cat) protein with Bcl-2 exhib-1991; Porras et al., 1994; Troppmair et al., 1994). Unlike
the experiments above, mitochondrial targeting se- ited significantly greater resistance to staurosporine,
compared with 32D.3 cells expressing Bcl-2 alone (p ,quences were not included in the active and inactive
Raf-1 proteins, thus making the association of these 0.05 by unpaired t test). None of the various 32D.3
transfectants, however, was resistant to staurosporine-proteins with mitochondrial membranes dependent on
interactions with Bcl-2. induced cell cycle arrest (data not shown), implying that
the enhanced resistance to this kinase inhibitor cannotImmunoblot analysis of the Bcl-2, Bcl-2–Raf-1(Cat),
and Bcl-2–Raf-1(K375W) cells using an antiserum spe- be explained by reduced import of the drug or acceler-
ated metabolism to inactive products.cific for the human Bcl-2 protein demonstrated essen-
tially equivalent amounts of plasmid-derived human Since Bcl-2 is well known for its ability to inhibit
staurosporine-induced apoptosis and because 32D.3Bcl-2 protein in these cells (see Figure 3A), the levels
of which were comparable to those in some human cells expressing the mitochondria-targeted Raf-1 pro-
tein exhibited increased resistance to staurosporine-tumor lines that overexpress Bcl-2 (data not shown).
Incubation of the same blot with an antiserum directed mediated cell death, it was important to determine
whether Raf-1 is a staurosporine-resistant or -sensitiveagainst a peptide corresponding to the C-terminus of
Raf-1 demonstrated the presence of the expected z35 kinase. For this purpose, Raf-1 was expressed in Sf9
cells by using a recombinant baculovirus that encodedkDa Raf-1(Cat) and z42 kDa Raf-1(K375W) proteins (see
Figure 3A). a mutant version of Raf-1 (259D) that has constitutively
high levels of kinase activity (Morrison et al., 1993; WangWhen deprived of IL-3, 32D.3 cells coexpressing Bcl-2
and Raf-1(Cat) exhibited prolonged survival compared et al., 1996). Immunoprecipitates of Raf-1(259D) protein
were then prepared from baculovirus-infected Sf9 cells,with cells expressing Bcl-2 alone (Figure 4B). In contrast,
32D.3 cells coexpressing Bcl-2 and Raf-1(K375W) had and the ability of this kinase to phosphorylate the sub-
strate protein GST–MEK in the presence or absence ofreduced survival compared with cells expressing Bcl-2
alone. The kinetics of cell death in cultures of 32D– various concentrations of staurosporine was tested. As
shown in Figure 5B, concentrations of staurosporine asBcl-2–Raf-1(K375W) cells, for instance, were essentially
the same as in the control 32D.3–Neo cells that lacked high as 5 mM had no inhibitory effect on Raf-1 kinase
activity, and even $10 mM had only modest effectsBcl-2 (Figure 4B), indicating that this dominant inhibitory
form of Raf-1 completely abrogated theprotective effect (,30% inhibition). From these studies, therefore, we
conclude first that targeting of activated Raf-1 kinaseof Bcl-2 on cell survival. Cells transfected with the plas-
mid encoding the active Raf-1(Cat) protein, without to mitochondria, either by fusion with the TM domain of
Mas70p or through its interaction with Bcl-2, promotesBcl-2, also displayed cell survival characteristics indis-
tinguishable from those of the Neo control cells (Wang resistance to staurosporine-induced apoptosis, and
second, that Raf-1 is a staurosporine-resistant kinase.et al., 1994), suggesting that Raf-1 inefficiently partici-
pates in the suppression of apoptosis in those cells
that contain relatively low levels of endogenous Bcl-2
Raf-1 Regulates the Phosphorylation of Differentprotein.
Proteins When Targeted to Plasma
Membrane versus Mitochondria
Since Bcl-2 can promote association of Raf-1 with mito-Raf-1 Cooperates with Bcl-2 in Suppressing
Staurosporine-Induced Apoptosis chondria, whereas Ras induces association of Raf-1
with the plasma membrane, it seems likely that activatedThe broad-specificity protein kinase inhibitor stauro-
sporine has been shown to induce apoptosis in essen- Raf-1 protein would encounter different substrates at
these two membrane sites. To explore this possibility,tially all types of cells derived from metazoan species
and thus has been used extensively as a general tool the state of phosphorylation of extracellular signal–
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and the gel mobility of ERK1 and ERK2 was compared.
Cells expressing the Raf-1–CAAX protein contained
both the unphosphorylated z42 kDa ERK1 and z44 kDa
ERK2 proteins as well as the higher molecular weight,
phosphorylated forms of ERK1 and ERK2 (Figure 6A).
In contrast, 32D.3 cells expressing M-Raf-1 and 32D.3
cells coexpressing Bcl-2 and untargeted Raf-1(Cat) con-
tained only the unphosphorylated forms of ERK1 and
ERK2. The differences in ERK1 and ERK2 phosphoryla-
tion seen in 32D.3 cells expressing the M-Raf-1 and Raf-
1–CAAX proteins cannot be attributed to lower levels of
the kinase activity in the former, since both the M-Raf-1
and Raf-1–CAAX proteins lacked the N-terminal regula-
tory region where Ras binds and were already maximally
active. These findings thus support the idea that tar-
geting of Raf-1 to different intracellular membrane com-
partments through its interactions with Ras (plasma
membrane) and Bcl-2 (mitochondrial membranes) pro-
motes the interactions of Raf-1 with different substrate
proteins.
What then are the substrates of Raf-1 at mitrochon-
drial membranes? Previously, we observed that while
Raf-1 can associate with Bcl-2, it does not normally
phosphorylate it (Wang et al., 1994). To explore the pos-
sibility that Raf-1 might phosphorylate other Bcl-2 family
proteins, baculovirus-produced Raf-1 (259D) protein
was tested for its ability to phosphorylate in vitro the
bacterially produced fusion proteins GST–Bcl-2, GST–
Bcl-XL, GST–Bcl-Xs, GST–Mcl-1, GST–Bax, GST–Bak,
and GST–BAD, making comparisons with the known
substrate GST–MEK. Among these various GST fusion
proteins, only GST–BAD and GST–MEK were phosphor-
ylated in vitro by Raf-1 (Figure 6B).
To determine whether the BAD protein becomes
phosphorylated in intact cells when Raf-1 is targeted to
mitochondria, 293 cells were transiently cotransfected
with a plasmid producing a hemagglutinin (HA) epitope–
tagged human BAD protein and plasmids producing the
various versions of Raf-1 described above: M-Raf-1,
Figure 5. Raf-1 Is a Staurosporine-Resistant Kinase
M-Raf-1(K375W), Raf-1–CAAX, or the parental plasmid
(A) Stably transfected 32D.3 cells were cultured in medium con-
(Neo) as a control. After 2 days, HA–BAD was analyzedtaining IL-3 and 1 mM staurosporine for 24 hr. The number of viable
by immunoblotting using an anti-HA monoclonal anti-cells relative to 32D.3-Neo was determined by MTT assay (mean 6
body. In addition to the z30 kDa HA–BAD protein thatSD; n = 3), which was set as 1.0. Similar results were obtained by
trypan blue dye exclusion assay (data not shown). was present in all transfectants, 293 cells expressing
(B) Active Raf-1(259D) kinase was incubated with 1 mg of GST–MEK the active M-Raf-1 protein, but not cells expressing the
and various concentrations of staurosporine with 20 mCi of M-Raf-1(K375W) or Raf-1–CAAX proteins, also con-
[32P]gATP. Phosphorylation of GST–MEK was analyzed by SDS– tained a slower-migrating z31 kDa form of HA–BAD
PAGE/autoradiography (top), and the results were quantified by b
(Figure 6C, lane 4). Treatment of the HA–BAD-containingscanning (bottom). Incubation of GST–MEK with anti-Raf-1 antise-
cell lysates with alkaline phosphatase removed the z31rum/protein A complexes lacking Raf-1 resulted in no detectable
kDa form (Figure 6C, lane 8), suggesting that it hadbackground phosphorylation (Wang et al., 1996; data not shown).
resulted from phosphorylation. Labeling cells with 32PO4
confirmed that M-Raf-1 induced phosphorylation of the
regulated protein kinases 1 and 2 (ERK1 and ERK2) BAD protein in intact cells, whereas M-Raf-1(K375W)
was examined. The ERK1 and ERK2 proteins become and Raf-1–CAAX did not (Figure 6D).
phosphorylated in a Ras-dependent manner by MAPK/
ERK kinase (MEK), a direct substrate of Raf-1 whose Discussion
enzymatic activity becomes elevated upon stimulation
of cells with various growth factors (Kyriakis et al., 1992). The findings reported here suggest a novel role for Raf-1
The phosphorylation of ERK1 and ERK2 results in a shift at mitochondrial membranes (and possibly other intra-
in their mobility upon SDS–polyacrylamide gel electro- cellular membranes where Bcl-2 resides) as a blocker of
phoresis (PAGE) to slower–migrating species that can apoptotic cell death, as opposed to its more traditionally
be detected by immunoblot analysis. known role as a promoter of cell proliferation and differ-
The 32D.3 cells expressing the M-Raf-1 and Raf-1– entiation within the context of the Ras signaling path-
ways at the plasma membrane. Several analogies canCAAX proteins were therefore deprived of IL-3 for 6 hr
Bcl-2-Mediated Targeting of Raf-1 to Mitochondria
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Figure 6. Differential Phosphorylation of
ERK1, ERK2, and BAD in 32D.3 Cells Ex-
pressing Mitochondria- and Plasma Mem-
brane–Targeted Active Raf-1
(A) Phosphorylation of ERK1 and ERK2
in 32D.3–Raf-1–CAAX, 32D.3–M-Raf-1, and
other transfectants was examined based on
altered migration of the phosphorylated pro-
teins in gels. Stably transfected 32D.3 cells
were cultured in the absence of IL-3 for 6 hr,
and lysates were prepared (25 mg per lane).
Data represent SDS–PAGE/immunoblotting
using anti-ERK rabbit antiserum.
(B) Raf-1(259D) was tested for ability to phos-
phorylate various GST fusion proteins in vitro
as described for Figure 5B. Anti-Raf antise-
rum/proteinA complexes lacking Raf-1(259D)
protein were used as a control (CNTL).
(C) 293 cells were transiently transfected with
20 mg of pcDNA3-HA-BAD and 20 mg of
pcDNA-3 plasmid (Neo) (lanes 1 and 5) or
pcDNA-3 encoding Raf-1-CAAX (lanes 2 and
6), M-Raf-1(K375W) (lanes 3 and 7), or
M-Raf-1 (lanes 4 and 8). After 2 days, the cells
were cultured in 0.5% serum for 6 hr, and cell
lysates (50 mg of total protein) were incubated
with 1 U of alkaline phosphatase at 378C for
4 hr in the presence (plus) or absence (minus) of phosphatase inhibitors prior to SDS–PAGE/immunoblot analysis using anti-HA monoclonal
antibody and ECL-based detection. Reprobing the same blot with anti-Raf antibody confirmed production of comparable amounts of the
M-Raf-1, M-Raf-1(K375W), and Raf-1–CAAX proteins (data not shown).
(D) 293 cells were transiently cotransfected with 20 mg of pFLAG-CMV2-BAD and 20 mg M-Raf-1, M-Raf-1(K375W), or Raf-1-CAAX-producing
plasmids and labeled with 32PO4 2 days later. FLAG–BAD protein was immunoprecipitated with anti-FLAG antibody, subjected to SDS–PAGE,
and transferred to nitrocellulose filters, followed by exposure to X-ray film to detect 32P-labeled FLAG–BAD (top). The blot was subsequently
probed with anti-FLAG antibody and developed by ECL, demonstrating comparable amounts of FLAG–BAD protein in all samples (bottom).
be drawn between the mechanisms by which p21ras and to the N-terminal regulatory domain of Raf-1 (Zhang et
al., 1993), Bcl-2 interacts with the C-terminal catalyticBcl-2 target Raf-1 to membranes. For example, because
the Bcl-2 protein resides in the outer mitochondrial domain (Wang et al., 1994). Indeed, it was this difference
in the locations on the Raf-1 protein where Bcl-2 andmembrane, with its C-terminal TM domain integrated
into membranes and the bulk of the protein oriented Ras bind that allowed us to explore the effects of consti-
tutively active and kinase-inactive Raf-1 mutants (whichtoward the cytosol (Krajewski et al., 1993; Lithgow et
al., 1994), we presume that the Bcl-2–Raf-1 interaction lacked the Ras-binding domain) on the Bcl-2 pathway
for suppression of apoptosis, in the absence of interfer-brings Raf-1 to the surface of the outer mitochondrial
membrane. Similarly, p21ras family proteins orient their ing effects on p21ras function.
Overexpression of Bcl-2 can inhibit cell proliferationC-termini toward the plasma membrane because of co-
valent attachment of lipids at the CAAX box motif and in some situations, perhaps by slowing the rate of pro-
gression through G1–S phase (Pietenpol et al., 1994;can bring Raf-1 from the cytosol to the plasma mem-
brane through Ras–Raf-1 protein–protein interactions Borner, 1996; Mazel et al., 1996). Given the ability of
p21ras and Bcl-2 to target Raf-1 to different membrane(Hall, 1994). Furthermore, just as targeting of Raf-1 to
plasma membranes by fusing the CAAX box motif onto compartments, with Raf-1 presumably participating in
pathways involved in mitogenesis at the plasma mem-Raf-1 has been shown to allow for Ras-independent
activation of Raf-1 and phosphorylation of the Raf-1 brane and other pathways related to cell survival control
at mitochondrial membranes, it is tempting to speculatesubstrate MEK (Stokoe et al., 1994; Leevers et al., 1994),
fusing activated Raf-1 with the TM domain Mas70p al- that this phenomenon of growth suppression by Bcl-2
may reflect a competition between Ras and Bcl-2 familylowed for Bcl-2-independent inhibition of apoptosis by
Raf-1. These similarities between Ras and Bcl-2 with proteins for limiting amounts of Raf-1.
Though Ras can target Raf-1 to plasma membranes,regards to interactions with Raf-1 emphasize the impor-
tance of protein–protein interactions for the intracellular resulting in activation of the kinase, it remains controver-
sial whether this protein–protein interaction is sufficienttargeting of kinases to sites of biological importance
(Faux and Scott, 1996). Presumably, it is through these to activate Raf-1. Indeed, the bulk of evidence supports
the idea that other proteins, including other protein ki-protein–protein interactions that specificity is achieved
in terms of targeting kinases to appropriate substrates, nases, are required for Ras-mediated activation of Raf-1
(Jelinek et al., 1996). In the experiments presented here,a concept supported by the differential phosphorylation
of ERK1, ERK2, and BAD shown here in 32D.3 cells we have bypassed the need for kinase activation by
deleting the negative regulatory domain of Raf-1. Theexpressing mitochondrial (M-Raf-1) and plasma (Raf-
1–CAAX) membrane–targeted versions of active Raf-1. question then is how is the kinase activity of Raf-1 nor-
mally turned on when brought into the vicinity of theAn interesting difference in the ways that p21ras pro-
teins and Bcl-2 interact with Raf-1 is that while Ras binds mitochondrial or other intracellular membranes where
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Bcl-2 resides? A potential answer has come recently cell death (Han et al., 1993; Lu et al., 1994; Tsuda et al.,
from the finding that another Bcl-2-associated protein, 1993). Moreover, the recently reported structure of the
BAG-1, can bind to and activate Raf-1 through an un- Bcl-XL protein suggests that Bcl-2 family proteins may
known mechanism (Wang et al., 1996). Like Bcl-2, the have intrinsic functions as pore-forming proteins (Much-
catalytic domain of Raf-1 is sufficient for the interaction more et al., 1996), irrespective of their interactions with
with BAG-1. Also, binding of BAG-1 to Bcl-2 is depen- other proteins. Thus, it seems unlikely that the Raf-1–
dent on the BH4 domain, similar to the interaction of Bcl-2 interaction is absolutely required for suppression
Raf-1 with Bcl-2. Thus, a preformed BAG-1–Raf-1 com- of apoptotic cell death. Nevertheless, the finding that
plex may bind to the BH4 domain of Bcl-2, thus bringing a dominant-inhibitory mutant of Raf-1 lacking kinase
Raf-1 to mitochondrial membranes associated with an activity completelyabrogated thesurvival-promoting ef-
activating protein, BAG-1. Alternatively, since Bcl-2 can fects of Bcl-2 in 32D.3 cells argues that Raf-1 can at
form dimers or larger oligomers (Oltvai et al., 1993; Sato least be a potent modulator of Bcl-2 function in some
et al., 1994), it is possible that Raf-1–BAG-1 complexes types of cells. The interaction of Raf-1 with Bcl-2, there-
assemble on Bcl-2 dimers/oligomers via interactions fore, may providea target for futureattempts atmodulat-
with BH4 domains on different Bcl-2 protein molecules. ing Bcl-2 protein activity for therapeutic benefit.
Clarifying the structural details of how these protein
complexes form and the precise mechanisms responsi- Experimental Procedures
ble for activation of Raf-1 in the vicinity of Bcl-2 repre-
Plasmidssents important issues for future investigations.
pcDNA3-Raf-1/CAAX chimeric plasmid encoding Raf-1(D26–303)Though it remains to be clarified what the substrates
joined with the 20 C-terminal amino acids of K-Ras at the C-terminusof Raf-1 are within its context as a Bcl-2-binding protein,
of Raf-1 was generated by polymerase chain reaction (PCR) muta-
the findings first that activated Raf-1 efficiently phos- genesis using the plasmids pRSV-BXB (Bruder et al., 1992) and
phorylates the BAD protein in vitro and second that BAD pZIP-raf/CAAX (gift of Channing Der) as templates and the primers
becomes phosphorylated incells expressing mitrochon- 59-CGGGCTCCTGGCTCCCTCAGGTTTAAGAATTG-39 (forward 1),
59-AATTGCTCTGGGGTTGGGTCGACAAC-39 (reverse 1), 59-TGCAGdria-targeted but not plasma membrane–targeted Raf-1
TAAAGATCCTAAAGGTTGTC-39 (forward 2), and 59-CGGGATCCTTsuggest (but do not prove) that BAD represents at least
ACATAATTACACACTTTGTC-39 (reverse 2). pcDNA3-Mas70/Raf-1one (but perhaps not the only) such substrate. At present
(Cat) and pcDNA3-Mas70/Raf-1(Cat)(K375W) containing the Mas-we do not know the functional significance of Raf-medi-
70p TM domain (residues 1–29) fused to the N-terminus of Raf-1
ated phosphorylation of the BAD protein. However, it (D26–303) or Raf-1(D26–303)(K375W) were generated by using the
might hypothetically prevent BAD from binding to Bcl-2 plasmids YEplac181-Mas70 (gift of Gottfried Schatz) (Hase et al.,
and Bcl-XL, thus relieving repression of these antiapop- 1984), pKSII-BXB, and pRSV-BXB(K375W) (Bruder et al., 1992) as
templates and the primers 59-GGAATTCGCCACCATGAAGAGCTTCtotic proteins by allowing them to homodimerize with
ATTACAAGG-39 (forward 1), 59-CCTGTATGTGCTCCATGTAATAATAthemselves, interact with other proteins, or form pores
GTAGGCACCGATGGC-39 (reverse 1), 59-TGCCTACTATTATTACATGin membranes.
GAGCACATACAGGGAGCTTG-39 (forward 2), and 59-CAGTCTAGAABcl-XS is the only known proapoptotic member of the GGTCCTTAGCAGAGC-39 (reverse 2). The pGFP-Raf-1(D26–303)
Bcl-2 family that contains a BH4 domain. Since Bcl-Xs plasmid was generated by subcloning the Raf-1(D26–303) cDNA
can interact wtih Raf-1, conceivably one mechanism by from pKSII-BXB into the pGFP-C1 (Clontech, Incorporated) by using
which Bcl-XS may antagonize the function of Bcl-2 is by EcoRI–XbaI sites. PCR-generated cDNAs encoding the human Bcl-2
(DTM) (i.e., without C-terminal TM domain), Bcl-XL(DTM), Bcl-competing with Bcl-2 for binding to Raf-1. However,
Xs(DTM), Mcl-1(DTM), Bax(DTM), Bak (DTM), BAD, and BAG-1 pro-since Bcl-XS probably resides in the same membrane
teins were subcloned into the EcoRI and XhoI sites of pGEX-4T-1,compartments with Bcl-2 (Gonza´lez-Garcia et al., 1994),
in-frame with GST, as described (Hanada et al., 1995). The human
there must be other reasons why Bcl-XS cannot substi- BAD cDNA was PCR-amplified from a HepG2 cDNA library
tute for Bcl-2 in either targeting Raf-1 to appropriate by using forward (59-GGAATTCATGTTCCAGATCCCAGAGTTTG
substrates or providing the means for activation of Raf-1 AGC-39) and reverse (59GCTCTAGATCACTGGGAGGGGGCGGAGC
TTCC-39) primers based on sequences of EST database cloneswithin the vicinity of mitochondrial or other internal
239688 and 301984. After digestion with EcoRI and XbaI, the BADmembranes. One likely explanation for the differential
cDNA was subcloned into the HA tag vector pShin-HA (Wang et al.,outcome of these interactions of Raf-1 with Bcl-2 versus
1996) and a modified version of the FLAG-tag vector pFLAG-CMV2.
Bcl-XS can be attributed to the capacity of the former All other plasmids have been described (Wang et al., 1994; Hanada
to dimerize with BAD and the inability of latter to do so et al., 1995).
(Sedlak et al., 1995), though other explanations are also
possible. Cell Transfections
The 32D.3 cells were maintained in IL-3-containing medium, and 20While the Bcl-2–Raf-1 interaction defines a novel regu-
mg of plasmid DNAs was introduced by electroporation as describedlatory event in the control of apoptosis, it is unclear
(Wang et al., 1994, 1995). The 293 cells were transfected by a calciumwhether it is essential for the function of Bcl-2 as a
phosphate method (Wang et al., 1996).
suppressor of cell death. The observation that Raf-1 is
a staurosporine-resistant kinase that can collaborate Coimmunoprecipitation Assay
with Bcl-2 in the inhibition of staurosporine-induced Infections of Sf9 cells with recombinant baculoviruses and coimmu-
noprecipitation assays were performed as described (Wang et al.,apoptosis is at least consistent with the idea that the
1994, 1995, 1996) with antisera specific for Raf-1, Bcl-2, Bcl-X, orBcl-2–Raf-1 interaction may be critical, inasmuch as
Bax, or normal rabbit serum (control) for immunoprecipitations andstaurosporine is a universal inducer of apoptosis (Weil
an anti-Raf-1 monoclonal antibody (URP30) for blotting.
et al., 1996). Genetic analysis of Raf-1 homologs in the
fly Drosophilia melanogaster (D-Raf) and the nematode In Vitro Protein Binding Assay
Caenorhabditis elegans (LIN-45), however, fail to sug- Sf9cells (8 3 107) were infected with GST–Raf-1 or GST–Raf-1(DCR3)
recombinant baculoviruses (MOI z10), and lysates were preparedgest an essential role for Raf in preventing programmed
Bcl-2-Mediated Targeting of Raf-1 to Mitochondria
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in 4 ml of Triton X-100 lysis buffer (150 mM NaCl, 10 mM Tris [pH mM, or 20 mM staurosporine. Phosphorylation of GST–MEK was
analyzed by SDS–PAGE/autoradiography, and the results were7.4], 5 mM EDTA [pH 8.0], 1% Triton X-100) containing 1 mM PMSF,
5 mg/ml leupeptin, and 5 mg/ml aprotinin. Lysates were mixed with quantified with a b-scanner (Bio-Rad, Incorporated). Alternatively,
1 mg of GST–BAD or other GST fusion proteins was added, instead100 ml of glutathione–Sepharose for 3 hr at 48C. The beads were
washed three times with 1 ml of NP-40 lysis buffer supplemented of GST–MEK.
with protease inhibitors and resuspended in 0.5 ml of the same
solution. GST-loaded beads (5 mg protein on z20 ml) were incubated Immunoblot and Immunoprecipitation Assays
with 10 ml of reticulocyte lysates (TNT-lysates; Promega, Incorpo- 32D.3 cells (5 3 106) were washed three times with Iscove’s modified
rated) containing in vitro translated [35S]methionine-labeled Bcl-2, Dulbecco’s medium (IMDM) and cultured in 10 ml IMDM containing
Bcl-2(DBH4), Bcl-XS, or Bax for 3 hr at 48C. After extensive washing 10% FCS without IL-3 for 6 hr. Cells were lysed in Triton X-100 lysis
in NP-40 lysis buffer, beads were boiled in Laemmli buffer and buffer containing protease inhibitors and phosphatase inhibitors (10
eluted proteins analyzed by SDS–PAGE (12% gels) and detected mM sodium b-glycerophosphate [pH 7.4], 1 mM Na3VO4, 5 mM NaF,
by fluorography. 2 mM Na4P2O7, 50 mM 4-nitrophenyl phosphate, and 1 mM microcys-
tin). The resulting lysates (25 mg per lane) were subjected to 10%
Yeast Two-Hybrid Assay SDS–PAGE immunoblot analysis (10% gels with 2% SDS) using 0.1
The cDNA fragments encoding Raf-1, Bcl-2(1–218) without its TM mg/ml anti-ERK rabbit antiserum (Santa Cruz Biotech, Incorporated),
domain, Bcl-2(1–218)(DBH4), Bcl-2(1–81), Bcl-2(1–81)(DBH4), Bcl- followed by 0.3 mg/ml horseradish peroxidase–goat anti-rabbit (Bio-
2(83–218), and Bax(1–171) without its TM were subcloned from Rad) and detection by an enhanced chemiluminescence (ECL) sys-
pEG202 (Hanada et al., 1995) into the two-hybrid vector pGilda (gift tem (Amersham).
of E. Golemis and D. Buckholtz), which produces fusion proteins After transfection (2 days), 293 cells were cultured in medium
with a LexA DNA-binding domain at the N-terminus under the control with 0.5% serum for 6 hr, and cell lysates (50 mg of total protein)
of a Gal1 promoter (Estojak et al., 1995). EGY191 strain yeast was were incubated with 1 U of alkaline phosphatase at 378C for 4 hr in
cotransformed with various pGilda expression plasmids incombina- the presence or absence of phosphatase inhibitors prior to SDS–
tion with various pJG4–5 plasmids, which produce B42 trans-activa- PAGE immunoblot analysis using anti-HA monoclonal antibody and
tion domain fusion proteins as described (Sato et al., 1994; Hanada ECL-based detection. Alternatively, the transfected cells were la-
et al., 1995). Filter assays were performed for b-galactosidase mea- beled with 32PO4 for 10 hr in phosphate-free Dulbecco’s modified
surements, by using cells plated on either galactose- or glucose- Eagle’s medium containing 0.5% dialyzed serum and 0.5 mCi/ml
containing MM medium supplemented with 20 mg/ml leucine. Colori- 32PO4. FLAG–BAD protein was immunoprecipitated with the M2 anti-
metric results were photographed after 2.5 hr. body (Kodak, Incorporated).
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